Cargando…
The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial
BACKGROUND: Exercise reduces the amount of visceral adipose tissue (VAT) and the risk of cardiometabolic diseases. The underlying mechanisms responsible for these exercise-induced adaptations are unclear, but they may involve lipolytic actions of interleukin-6 (IL-6). Contracting skeletal muscles se...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932829/ https://www.ncbi.nlm.nih.gov/pubmed/29720225 http://dx.doi.org/10.1186/s13063-018-2637-0 |
_version_ | 1783319878186303488 |
---|---|
author | Christensen, Regitse Højgaard Wedell-Neergaard, Anne-Sophie Lehrskov, Louise Lang Legård, Grit Elster Dorph, Emma Berndt Nymand, Stine Ball, Maria Korf Zacho, Morten Christensen, Robin Ellingsgaard, Helga Rosenmeier, Jaya Birgitte Krogh-Madsen, Rikke Pedersen, Bente Klarlund Karstoft, Kristian |
author_facet | Christensen, Regitse Højgaard Wedell-Neergaard, Anne-Sophie Lehrskov, Louise Lang Legård, Grit Elster Dorph, Emma Berndt Nymand, Stine Ball, Maria Korf Zacho, Morten Christensen, Robin Ellingsgaard, Helga Rosenmeier, Jaya Birgitte Krogh-Madsen, Rikke Pedersen, Bente Klarlund Karstoft, Kristian |
author_sort | Christensen, Regitse Højgaard |
collection | PubMed |
description | BACKGROUND: Exercise reduces the amount of visceral adipose tissue (VAT) and the risk of cardiometabolic diseases. The underlying mechanisms responsible for these exercise-induced adaptations are unclear, but they may involve lipolytic actions of interleukin-6 (IL-6). Contracting skeletal muscles secrete IL-6, leading to increased circulating IL-6 levels in response to exercise. The aim of this study is to investigate whether IL-6 is involved in mediating the effects of exercise on visceral and epicardial adipose tissue volume and glycaemic control. METHODS/DESIGN: Seventy-five physically inactive males and females aged > 18 years with a waist-to-height ratio > 0.5 and/or waist circumference ≥ 88 cm (females) or ≥ 102 cm (males) are being recruited to participate in a 12-week intervention study. Participants are randomly allocated to one of five groups (1:1:1:1:1). Two groups consist of supervised endurance exercise training combined with the IL-6 blocker tocilizumab (ET) or saline used as placebo (EP), two groups consist of no exercise combined with tocilizumab (NT) or placebo (NP), and one group consists of resistance exercise and placebo (RP). Although the study is an exploratory trial, the primary outcome is change in VAT volume from before to after intervention, with secondary outcomes being changes in (1) epicardial adipose tissue, (2) pericardial adipose tissue and (3) gastric emptying. Depots of adipose tissue are quantitated by magnetic resonance imaging Gastric emptying and glucose metabolism are assessed using mixed-meal tolerance tests. DISCUSSION: Understanding the role of IL-6 in mediating the effects of exercise on visceral and epicardial adipose tissue and glycaemic control may lead to novel therapeutic approaches in the prevention of cardiometabolic diseases. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02901496. Registered on 1 August 2016 and posted retrospectively on 15 September 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2637-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5932829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59328292018-05-09 The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial Christensen, Regitse Højgaard Wedell-Neergaard, Anne-Sophie Lehrskov, Louise Lang Legård, Grit Elster Dorph, Emma Berndt Nymand, Stine Ball, Maria Korf Zacho, Morten Christensen, Robin Ellingsgaard, Helga Rosenmeier, Jaya Birgitte Krogh-Madsen, Rikke Pedersen, Bente Klarlund Karstoft, Kristian Trials Study Protocol BACKGROUND: Exercise reduces the amount of visceral adipose tissue (VAT) and the risk of cardiometabolic diseases. The underlying mechanisms responsible for these exercise-induced adaptations are unclear, but they may involve lipolytic actions of interleukin-6 (IL-6). Contracting skeletal muscles secrete IL-6, leading to increased circulating IL-6 levels in response to exercise. The aim of this study is to investigate whether IL-6 is involved in mediating the effects of exercise on visceral and epicardial adipose tissue volume and glycaemic control. METHODS/DESIGN: Seventy-five physically inactive males and females aged > 18 years with a waist-to-height ratio > 0.5 and/or waist circumference ≥ 88 cm (females) or ≥ 102 cm (males) are being recruited to participate in a 12-week intervention study. Participants are randomly allocated to one of five groups (1:1:1:1:1). Two groups consist of supervised endurance exercise training combined with the IL-6 blocker tocilizumab (ET) or saline used as placebo (EP), two groups consist of no exercise combined with tocilizumab (NT) or placebo (NP), and one group consists of resistance exercise and placebo (RP). Although the study is an exploratory trial, the primary outcome is change in VAT volume from before to after intervention, with secondary outcomes being changes in (1) epicardial adipose tissue, (2) pericardial adipose tissue and (3) gastric emptying. Depots of adipose tissue are quantitated by magnetic resonance imaging Gastric emptying and glucose metabolism are assessed using mixed-meal tolerance tests. DISCUSSION: Understanding the role of IL-6 in mediating the effects of exercise on visceral and epicardial adipose tissue and glycaemic control may lead to novel therapeutic approaches in the prevention of cardiometabolic diseases. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02901496. Registered on 1 August 2016 and posted retrospectively on 15 September 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2637-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-02 /pmc/articles/PMC5932829/ /pubmed/29720225 http://dx.doi.org/10.1186/s13063-018-2637-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Christensen, Regitse Højgaard Wedell-Neergaard, Anne-Sophie Lehrskov, Louise Lang Legård, Grit Elster Dorph, Emma Berndt Nymand, Stine Ball, Maria Korf Zacho, Morten Christensen, Robin Ellingsgaard, Helga Rosenmeier, Jaya Birgitte Krogh-Madsen, Rikke Pedersen, Bente Klarlund Karstoft, Kristian The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title | The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title_full | The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title_fullStr | The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title_full_unstemmed | The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title_short | The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
title_sort | role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932829/ https://www.ncbi.nlm.nih.gov/pubmed/29720225 http://dx.doi.org/10.1186/s13063-018-2637-0 |
work_keys_str_mv | AT christensenregitsehøjgaard theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT wedellneergaardannesophie theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT lehrskovlouiselang theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT legardgritelster theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT dorphemmaberndt theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT nymandstine theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT ballmariakorf theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT zachomorten theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT christensenrobin theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT ellingsgaardhelga theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT rosenmeierjayabirgitte theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT kroghmadsenrikke theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT pedersenbenteklarlund theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT karstoftkristian theroleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT christensenregitsehøjgaard roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT wedellneergaardannesophie roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT lehrskovlouiselang roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT legardgritelster roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT dorphemmaberndt roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT nymandstine roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT ballmariakorf roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT zachomorten roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT christensenrobin roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT ellingsgaardhelga roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT rosenmeierjayabirgitte roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT kroghmadsenrikke roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT pedersenbenteklarlund roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial AT karstoftkristian roleofexercisecombinedwithtocilizumabinvisceralandepicardialadiposetissueandgastricemptyingrateinabdominallyobeseparticipantsprotocolforarandomisedcontrolledtrial |